Nanobac Operating Cycle from 2010 to 2024

NNBP Stock  USD 0.0001  0.00  0.00%   
Nanobac Pharmaceuticals Operating Cycle yearly trend continues to be relatively stable with very little volatility. Operating Cycle is likely to grow to 281.35 this year. During the period from 2010 to 2024, Nanobac Pharmaceuticals Operating Cycle destribution of quarterly values had range of 239 from its regression line and mean deviation of  30.71. View All Fundamentals
 
Operating Cycle  
First Reported
2010-12-31
Previous Quarter
267.95
Current Value
281.35
Quarterly Volatility
61.32556572
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Nanobac Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Nanobac Pharmaceuticals' main balance sheet or income statement drivers, such as Interest Expense of 0.0, Selling General Administrative of 2.6 M or Total Revenue of 15.1 K, as well as many indicators such as Price To Sales Ratio of 90.9, Days Sales Outstanding of 56.52 or Invested Capital of 0.0. Nanobac financial statements analysis is a perfect complement when working with Nanobac Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Nanobac Pharmaceuticals Correlation against competitors.

Additional Tools for Nanobac Stock Analysis

When running Nanobac Pharmaceuticals' price analysis, check to measure Nanobac Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nanobac Pharmaceuticals is operating at the current time. Most of Nanobac Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Nanobac Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nanobac Pharmaceuticals' price. Additionally, you may evaluate how the addition of Nanobac Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.